68 results
Page 2 of 4
8-K
EX-10.1
8qvac
13 Sep 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
9:59pm
424B3
58qrs
6 Jul 22
Prospectus supplement
2:43pm
8-K
EX-10.1
wvuhbx
3 Jun 22
Entry into a Material Definitive Agreement
9:51pm
8-K
EX-10.2
z1m52o
3 Jun 22
Entry into a Material Definitive Agreement
9:51pm
424B5
ymx77zzivo7rjgkr1vi8
3 Jun 22
Prospectus supplement for primary offering
9:45pm
424B3
xzz26rf3g91mkqrf8
25 Apr 22
Prospectus supplement
5:02pm
8-K
EX-10.1
pvt8ilx21yea
7 Apr 22
Entry into a Material Definitive Agreement
4:47pm
424B3
3irbuga
7 Apr 22
Prospectus supplement
4:46pm
S-3
esce9y7
4 Feb 22
Shelf registration
4:36pm
8-K
EX-99.1
2cyjm
5 Jan 22
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook
2:22pm
DEF 14A
vk8avt40id538 d08bad
28 Oct 21
Definitive proxy
3:07pm
8-K
EX-2.1
bh7ousqyva31xmq
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm
10-K
EX-2.1
nncw6pwi2 z4bcsc91z
24 Sep 21
Annual report
7:31am